Call  +41 61 926 6040
Fax +41 61 926 6049
Toggle Nav
My Cart
Search
Advanced Search
Account
Settings

Immunology

Toggle Nav

Items 151-160 of 392

Page
per page
Set Descending Direction
  1. Fc (human):BAFF (human) (rec.)
    AG-40B-0120
    AG-40B-0120-C01010 µg
    CHF 230.00
    AG-40B-0120-30103 x 10 µg
    CHF 460.00
    AG-40B-0120-C500500 µg
    CHF 2'400.00
    Add to Compare
    Learn More
    Restoration of the splenic T and B cell architecture in Fc-BAFF injected BAFFdeficient mice. BAFF deficient mice were injected at day 0 with 100mg BAFF (human):Fc (human) (AG-40B-0120) intravenously and at day 14 with 50mg BAFF (human):Fc (human) intraper
  2. Fc (human):CD137L, Soluble (human) (rec.)
    AG-40B-0173
    AG-40B-0173-C01010 µg
    CHF 265.00
    AG-40B-0173-30103 x 10 µg
    CHF 530.00
    Add to Compare
    Learn More
    Fc (human):CD137L, Soluble (human) (rec.) (AG-40B-0173) binds to human CD137. Method: CD137 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of Fc (human):CD137L, Soluble (human) (AG-40B-
  3. Fc (human):FasL, Soluble (human) (rec.)
    AG-40B-0132
    AG-40B-0132-C01010 µg
    CHF 335.00
    AG-40B-0132-30103 x 10 µg
    CHF 670.00
    Add to Compare
    Learn More
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Pr
  4. Fc (human):FGL1 (human) (rec.)
    AG-40B-0184
    AG-40B-0184-C01010 µg
    CHF 240.00
    AG-40B-0184-30103 x 10 µg
    CHF 480.00
    AG-40B-0184-C100100 µg
    CHF 1'140.00
    Add to Compare
    Learn More
  5. Fc (human):FLT3 Ligand (human) (rec.)
    AG-40B-0119
    AG-40B-0119-C01010 µg
    CHF 240.00
    AG-40B-0119-30103 x 10 µg
    CHF 480.00
    AG-40B-0119-C100100 µg
    CHF 960.00
    Add to Compare
    Learn More
    Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 μg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.
  6. Fc (human):Grancalcin (human) (rec.)
    AG-40B-0242
    AG-40B-0242-C05050 µg
    CHF 440.00
    Add to Compare
    Learn More
  7. Fc (human):OX40L, Soluble (human) (rec.)
    AG-40B-0172
    AG-40B-0172-C01010 µg
    CHF 230.00
    AG-40B-0172-30103 x 10 µg
    CHF 455.00
    Add to Compare
    Learn More
  8. Fc (LAEA-PG)-KIH (mouse) IgG2b Control (rec.)
    AG-35B-0019
    AG-35B-0019-C05050 µg
    CHF 340.00
    Add to Compare
    Learn More
    NEW Fc (LAEA-PG)-KIH (mouse) IgG2b Control (rec.)
  9. Fc (LALA-PG)-KIH (human) IgG1 Control (rec.)
    AG-35B-0018
    AG-35B-0018-C05050 µg
    CHF 340.00
    Add to Compare
    Learn More
    Fc (LALA-PG)-KIH (human) IgG1 Control (rec.)
  10. Fc (LALA-PG)-KIH (human):GDF15 (human) (rec.)
    AG-40B-0253
    AG-40B-0253-C05050 µg
    CHF 440.00
    Add to Compare
    Learn More
    NEW Fc (LALA-PG)-KIH (human):GDF15 (human) (rec.)

Items 151-160 of 392

Page
per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.